Hyperpolarized Pyruvate

Phase 2Small molecule

Hyperpolarized Pyruvate is one of 30 small molecule programs targeting Traumatic Brain Injury. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Traumatic Brain InjuryEnrolling by invitation

Primary CNS LymphomaRecruiting

High Risk Prostate CarcinomaActive, not recruiting

Malignant Solid TumorsRecruiting

Traumatic Brain InjuryPhase 1

Enrolling by invitation

Primary CNS LymphomaPhase 1

Recruiting

High Risk Prostate CarcinomaPhase 2

Active, not recruiting

Malignant Solid TumorsPreclinical

Recruiting

Competition

Competitive Landscape

18 competitors in Malignant Solid Tumors

#DrugCompanyPhaseTrials

Zometa

Pfizer

Phase 3

1 2

Scemblix

Novartis

Phase 2

1 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 2

1 4

Paraplatin

AAvyxa

Phase 2

1 5

Vepesid

AAvyxa

Phase 2

1 6

RC148

RRemeGen Co., Ltd.

Phase 2

1 7

SHR-1316

Suzhou Suncadia Biopharmaceuticals Co., Ltd.

Phase 2

1 8

JMT103

SShanghai JMT-Bio Inc.

Phase 3

1 9

Hyperpolarized Pyruvate

SSunnybrook Health Sciences Centre

Phase 2

1 10

BP102

Shanghai Hengrui Pharmaceutical Co., Ltd.

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Primary CNS Lymphoma

NCT04656431

Q2 2027

Phase 1Recruiting

Imaging

NCT02648009

PreclinicalRecruiting

Malignant Solid Tumors

NCT02421380

Q2 2031

Phase 2Active, not recruiting

High Risk Prostate Carcinoma

NCT06384222

Clinical

Trials by Indication[1]

Prostate Cancer2 trials

Hyperpolarized Pyruvate Injection in Subjects With Prostate Cancer

Completed·UUniversity of California, San Francisco·Phase 1·NCT01229618·31 enrolled

Multiparametric MRI for Prostate Cancer Localization and Characterization Using Hyperpolarized Pyruvate (13C) Injection

Withdrawn·SSunnybrook Health Sciences Centre·Phase 1·NCT02647983

Imaging1 trial

Metabolic Imaging of the Heart Using Hyperpolarized (13C) Pyruvate Injection

Recruiting·SSunnybrook Health Sciences Centre·Phase 1·NCT02648009·112 enrolled

Toxicity1 trial

Pilot Study of Safety and Toxicity of Acquiring Hyperpolarized Carbon-13 Imaging in Children With Brain Tumors

Completed·UUniversity of California, San Francisco·Phase 1·NCT02947373·10 enrolled

Breast Cancer1 trial

Study to Evaluate the Feasibility of 13-C Pyruvate Imaging in Breast Cancer Patients Receiving Neoadjuvant Chemotherapy

Withdrawn·SSunnybrook Health Sciences Centre·Phase 1·NCT03121989

Glioblastoma1 trial

Evaluating Hyperpolarized and Proton Brain Metabolism in Patients With Glioblastoma

Terminated·SSusan Chang·Phase 1·NCT04019002·17 enrolled

4 more indications

High Risk Prostate Carcinoma1 trial

Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) as a Response Monitoring Tool in Patients With High-Risk Prostate Cancer Receiving Neoadjuvant Therapy

Active, not recruiting·IIvan de Kouchkovsky, MD·Phase 2·NCT06384222·32 enrolled

Traumatic Brain Injury1 trial

Imaging of Traumatic Brain Injury Metabolism Using Hyperpolarized Carbon-13 Pyruvate

Enrolling by invitation·UUniversity of Texas Southwestern Medical Center·Phase 1·NCT03502967·60 enrolled

Malignant Solid Tumors1 trial

Characterization of Hyperpolarized Pyruvate MRI Reproducibility

Recruiting·MMemorial Sloan Kettering Cancer Center·Preclinical·NCT02421380·109 enrolled

Primary CNS Lymphoma1 trial

Pilot Study of Feasibility of Acquiring Hyperpolarized Imaging in Patients With Primary CNS Lymphoma

Recruiting·JJames Rubenstein·Phase 1·NCT04656431·26 enrolled

Sources

References

[1]
ClinicalTrials.gov — 10 trial records for Hyperpolarized Pyruvate. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Hyperpolarized Pyruvate compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Hyperpolarized Pyruvate. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Sunnybrook Health Sciences Centre company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSunnybrook Health Sciences Centre

Hyperpolarized Pyruvate

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q2 2027

Q2 2031

Trials by Indication[1]

Prostate Cancer2 trials

Imaging1 trial

Toxicity1 trial

Breast Cancer1 trial

Glioblastoma1 trial

High Risk Prostate Carcinoma1 trial

Traumatic Brain Injury1 trial

Malignant Solid Tumors1 trial

Primary CNS Lymphoma1 trial

References

Drug Info

Quick Facts

Related News